Teng Moua

Oct 22, 2024 | mdpi.com | Teng Moua |Misbah Baqir |Jay H. Ryu

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal disease characterized by the accumulation of fibrotic tissue in the lung [1]. While two antifibrotic medications (nintedanib and pirfenidone) [2,3] have been shown to slow disease progression and are currently in use, a significant need remains for more effective agents that may prevent loss of lung function and even reverse fibrosis.